Dr. Sara Nagy, Department of Neurology, University Hospital Basel
Chronic inflammatory demyelinating neuropathy from a genetic viewpoint: genome-wide association study and epigenetic investigations
Dr. Bettina Schreiner, Dr Florian Ingelfinger, Institute of Experimental Immunology University of Zurich
Investigating the link between genetic variation and inflammatory cytokine responses in patients with Myasthenia gravis
Dr. Susan Treves, Department of Biomedicine, University of Basel
Impact of RYR1 mutations on muscle spindle function and their effect on the musculoskeletal system
Dr. Bettina Henzi, Pediatric Neurology, University Children's Hospital, Basel
Analysis of exploratory endpoints of the clinical trial: To a personalized treatment with Tamoxifen in Duchenne muscular dystrophy
Dr. Nicholas Sanderson, Clinical Neuroimmunology, Department of Biomedicine University of Basel and University Hospital
Receptor-Antagonizing Antibodies in Myasthenia Gravis
PD Dr. Isabel Filges, Medizinische Genetik, University Hospital Basel
Phenotype-genotype correlations and the natural history of neuromuscular arthrogryposis - towards a Swiss reference center
PD Dr. Regina Schläger, Department of Neurology, University Hospital Basel
Quantitative Spinal Cord Gray and White Matter Imaging in Amyotrophic
Lateral Sclerosis - a post - mortem validation study
Prof. Stephan Frank, Neuro and Ophthalmopathology, Institute of Pathology, University of Basel
DNA methylation-profiling for the molecular classification of inflammatory myopathies
Prof. Susan Treves, Departments of Anesthesia and Biomedicine, University of Basel
Pharmacological treatment of disorders due to recessive RYR1 mutations: effect of class II HDAC inhibitors
Dr. Nicholas Sanderson, Department of Clinical Neuroimmunology
University of Basel and University Hospital
Screening, Isolation and Analysis of Autoantigen-specific B cells in Myasthenia Gravis
Prof. Hans H. Jung, Department of Neurology, University Hospital Zürich
Clinical and genetic characterization, natural history and biomarkers in Swiss patients with inherited peripheral neuropathies
Dr. Simone Schmidt, Neuropediatric Department, University Children’s Hospital Basel
Observational follow-up of Duchenne muscular dystrophy patients from the DMD02 trial
Prof. Susan Treves, Departments of Anesthesia and Biomedicine, University of Basel
Dysregulation of excitation contraction coupling and ophthalmoplegia in a mouse model knocked in for compound heterozygous ryanodine receptor (RYR1) mutations
Dr. Ruben Herrendorff, Pharmazentrum, University of Basel
Anti-MAG neuropathy mouse model and in vivo validation of PN-1007 (continuation 2nd year)
Dr. Paolo Ripellino, Neurocenter of Southern Switzerland, Ospedale Civico, Lugano
Autoantibodies related to HEV-induced neuralgic amyotrophy
Dr. Ruben Herrendorff, Pharmazentrum, University of Basel
Anti-MAG neuropathy mouse model and in vivo validation of PN-1007
Dr. Bernhard Schneider, Brain & Mind Institute, EPFL, Lausanne and Dr. Roman Chrast, Department of Neuroscience, Karolinska, Stockholm
An integrative approach to characterize (and potentially prevent) alterations in neurons, glia and muscle cells induced by CMT2A, an axonal form of neuropathy
Dr. Jérôme N. Feige, Nestlé Institute of Health Sciences, EPFL, Lausanne
Cholesterol metabolism in Schwann cells during neuromuscular aging
Prof. Markus A. Rüegg, Biozentrum, University of Basel
Repair of laminin-deficient muscular dystrophy with synthetic linker proteins
Prof. Dr. med. Michael Sinnreich, Neuromuskuläres Zentrum, Neurologie,
Universitätsspital Basel
Understanding the pathomechanism leading to Myotonic Dystrophy type 1: Role of mTORC1 imbalance and autophagy impairment in DM1-associated alterations of skeletal muscle
Prof. Dr. med. Hans Jung, Department of Neurology, University Hospital, Zurich
Influence of physical activity on mitochondrial function in mitochondrial myopathies, Huntington disease and normal aging
Prof. Dr. Christoph Handschin, Biozentrum, University of Basel,
Global analysis of RNA processing in muscle cell-motor neuron co-cultures of spinal muscular atrophy (SMA) patients
Dr. Christian Neuwirth and Prof. Markus Weber, Muskelzentrum ALS clinic, Kantonsspital St.Gallen
A novel neurophysiological measurement (MUNIX) in neuromuscular disorders, test-retest reliability and longitudinal follow-up measurements in amyotrophic lateral sclerosis patients in a multi-centre study
Dr. Susan Treves, Perioperative Patient Safety Group, Departement Biomedizin, University Hospital Basel
Myopathies caused by recessive ryanodine receptor (RYR1) mutations: is there a causative link between abnormal microRNA expression and reduced ryanodine receptor protein expression
Prof. Dr. Michael Sinnreich and Ruben Herrendorff, Msc, Departments of Biomedicine and Neurology, Neuromuscular Research, Basel
Identification of novel lead compounds for the treatment of Myotonic Dystrophy type 1
Dr. Stefania Puttini, Laboratory of molecular Biotechnology, University of Lausanne
miRNAs as serum biomarkers for diagnosis of degenerative or inflammatory myopathies
Dr. Lionel Tintignac, Biozentrum University of Basel
Inhibition of myocellular breakdown for the prevention of disease-associated muscle weakness
Prof. Dr. med. S. Frank,
Department of Neuropathology, Institute of
Pathology, University of Basel
Exploring the role of the mitochondrial fission protein DRP1 in motoneuron function and survival
PD Dr. med. D. Fischer,
Departments of Pediatrics and Neurology, University Hospital Basel
A pilot study to evaluate the effect of L-arginine and metformin in Duchenne’s muscular dystrophy
Prof. Dr. Michael Sinnreich, Department of Biomedicine, Pharmazentrum, Neuromuscular Research, Basel
Novel sequence capture method for molecular diagnostics of neuromuscular diseases
Prof. Dr. Roman Chrast, Department of Medical Genetics, Lausanne
Analysis of the role of Sh3tc2, protein affected in Charcot-Marie-Tooth 4C disease, in the regulation of Schwann cell myelination
PD Dr. S. Treves, Departments of Anesthesia + Biomedicine, Basel University Hospital, Basel
The effect of mutations in the ryanodine receptor calcium channel and its link to the neuromuscular disorders Central Core disease, Multiminicore disease and Malignant Hyperthermia
Prof. H.R. Brenner, Department of Biomedicine, Pharmazentrum, Basel
Neuronal Agrin and acetylcholine receptor dynamics at the neuromuscular junction in vivo
Prof. Markus A. Rüegg, Pharmacology/Neurobiology, Biozentrum, Basel
Does the angiotensin II type 1 receptor antagonist losartan ameliorate disease progression in MDC1A?
PD. Dr. Susanne Renaud, Neurology, University Hospital, Basel
Molecular biological characterization of skin biopsies of patients suffering from inflammatory and dysimmune polyneuropathies